A clinical case of the X-linked moesin deficiency

2021 ◽  
Vol 17 (4) ◽  
pp. 90-94
Author(s):  
Tatiana V. Latysheva ◽  
Elena A. Latysheva ◽  
Nelly H. Setdikova ◽  
Daria R. Esaulova

With the increasing availability of genetic testing, the population of patients diagnosed with CVID breaks down into groups depending on monogenic defects. There is more and more evidence that adults can have combined immunodeficiencies with a late onset. This article discusses a clinical case of X-linked moesin-associated immunodeficiency (X-MAID). This is a recently described immunodeficiency, which mostly manifests itself at an early age with severe lymphopenia and hypogammaglobulinemia, fluctuating monocytopenia and neutropenia, a weak immune response to vaccine antigens, and increased susceptibility to bacteria and type 3 human herpesvirus. X-MAID, X-linked immunodeficiency with a recessive mode of inheritance, is caused by genetic defects in the MOESIN gene (membrane organizing spike elongation protein, MSN). Until recently, there were records of 10 people with this mutation, 9 of which have the phenotype of severe combined immunodeficiency (SCID). The patient described in this article has been under observation since the age of 12 and diagnosed with SCID due to an IgG decrease accompanied by infectious-purulent processes of the respiratory tract and diarrheal syndrome. However, the patient did not entirely fit into the typical clinical picture of CVID due to a severe therapy-torpid papillomavirus infection, the increased number of switched memory B-cells, IgG isolated decrease, persistent severe leukopenia and lymphopenia of CD4+ cells. In accordance with the clinical picture and the results of the immunological examination, combined immunodeficiency was surmised. After a full exome DNA sequencing chrX: g.64951012C T missense type mutation was found in exon 5 of the MSN gene (change in the ENSP00000353408.5:p.Arg171Trp protein). X-MAID was therefore confirmed. Of the 9 described patients with a similar mutation, 8 had a clinical picture of severe combined immune deficiency. This clinical case confirms the possibility of a milder clinical phenotype development with a late onset under the guise of CVID and shows the need for molecular genetic examination of the adult population of patients with impaired antibody synthesis. The verification of the diagnosis allows not only to determine the prognosis and tactics of the therapy, but also to carry out genetic family counseling and to offer a possibility of giving birth to healthy offspring.

The Lancet ◽  
1994 ◽  
Vol 344 (8933) ◽  
pp. 1361-1362 ◽  
Author(s):  
AnneL. Appleton ◽  
J.S.Malik Peiris ◽  
CliveE. Taylor ◽  
Lisbet Sviland ◽  
AndrewJ. Cant

Blood ◽  
2012 ◽  
Vol 120 (18) ◽  
pp. 3635-3646 ◽  
Author(s):  
Fabio Candotti ◽  
Kit L. Shaw ◽  
Linda Muul ◽  
Denise Carbonaro ◽  
Robert Sokolic ◽  
...  

AbstractWe conducted a gene therapy trial in 10 patients with adenosine deaminase (ADA)–deficient severe combined immunodeficiency using 2 slightly different retroviral vectors for the transduction of patients' bone marrow CD34+ cells. Four subjects were treated without pretransplantation cytoreduction and remained on ADA enzyme-replacement therapy (ERT) throughout the procedure. Only transient (months), low-level (< 0.01%) gene marking was observed in PBMCs of 2 older subjects (15 and 20 years of age), whereas some gene marking of PBMC has persisted for the past 9 years in 2 younger subjects (4 and 6 years). Six additional subjects were treated using the same gene transfer protocol, but after withdrawal of ERT and administration of low-dose busulfan (65-90 mg/m2). Three of these remain well, off ERT (5, 4, and 3 years postprocedure), with gene marking in PBMC of 1%-10%, and ADA enzyme expression in PBMC near or in the normal range. Two subjects were restarted on ERT because of poor gene marking and immune recovery, and one had a subsequent allogeneic hematopoietic stem cell transplantation. These studies directly demonstrate the importance of providing nonmyeloablative pretransplantation conditioning to achieve therapeutic benefits with gene therapy for ADA-deficient severe combined immunodeficiency.


Blood ◽  
1979 ◽  
Vol 53 (3) ◽  
pp. 465-471 ◽  
Author(s):  
CH Lee ◽  
SP Evans ◽  
MC Rozenberg ◽  
AS Bagnara ◽  
JB Ziegler ◽  
...  

Abstract The platelets of an infant with severe combined immune deficiency and adenosine deaminase deficiency showed markedly diminished responses to ADP-induced aggregation in vitro. This abnormality was corrected by the addition of purified adenosine deaminase in vitro. Exogenous adenosine added to platelet-rich plasma caused markedly prolonged inhibition of ADP-induced aggregation. This was shown by isotopic studies to be due to slow clearance of adenosine and hence persistence of this nucleoside. Direct assay for adenosine deaminiase in plasma and platelet lysates of the patient confirmed the very low activity of this enzyme. Raised cAMP levels were demonstrated in his platelets. The deranged adenosine metabolism and raised cAMP in the platelets of this child with severe combined immunodeficiency may explain the altered response to ADP. Despite the in vitro platelet aggregation abnormality, the patient had no clinical evidence of impaired hemostasis.


Blood ◽  
1979 ◽  
Vol 53 (3) ◽  
pp. 465-471
Author(s):  
CH Lee ◽  
SP Evans ◽  
MC Rozenberg ◽  
AS Bagnara ◽  
JB Ziegler ◽  
...  

The platelets of an infant with severe combined immune deficiency and adenosine deaminase deficiency showed markedly diminished responses to ADP-induced aggregation in vitro. This abnormality was corrected by the addition of purified adenosine deaminase in vitro. Exogenous adenosine added to platelet-rich plasma caused markedly prolonged inhibition of ADP-induced aggregation. This was shown by isotopic studies to be due to slow clearance of adenosine and hence persistence of this nucleoside. Direct assay for adenosine deaminiase in plasma and platelet lysates of the patient confirmed the very low activity of this enzyme. Raised cAMP levels were demonstrated in his platelets. The deranged adenosine metabolism and raised cAMP in the platelets of this child with severe combined immunodeficiency may explain the altered response to ADP. Despite the in vitro platelet aggregation abnormality, the patient had no clinical evidence of impaired hemostasis.


2020 ◽  
Vol 41 (2) ◽  
pp. 134-140
Author(s):  
Yuriy Bisyuk ◽  
Andrew Dubovyi ◽  
Ilona DuBuske ◽  
Viktor Litus ◽  
Lawrence M. DuBuske

Background: This study assessed gene polymorphisms of the CD14 receptor (C-159T) and Toll-like receptor 4 (Asp299Gly) in a patient population in Crimea, Ukraine, stratified by clinical (early versus late onset; frequent versus occasional relapses; fixed versus reversible obstruction) and immunologic (atopic versus nonatopic; eosinophilic; neutrophilic or paucigranulocytic inflammation) subtype. Methods: Two polymorphisms, CD14 C-159T and TLR4 Asp299Gly, were assessed in 331 patients with asthma. The control group included 285 volunteers who were nonatopic. The single nucleotide polymorphisms were studied by using polymerase chain reaction with electrophoretic detection. Results: There were increased odds of asthma development in patients with the Asp299Gly TLR4 mutation compared with the general population underdominant odds ratio (OR) 1.52 [95% confidence interval (CI), 1.00‐2.32] and overdominant (OR 1.55 [95% CI, 1.01‐2.38]) models after adjustment for gender and age. In addition, mutations in this gene decreased the odds of nonatopic asthma in underdominant (OR 0.26 [95% CI, 0.07‐0.93]; p = 0.027), overdominant (OR 0.27 [95% CI, 0.07‐0.96]; p = 0.033), and log-additive models (OR 0.26 [95% CI, 0.07‐0.93]; p = 0.026) compared with the atopic subgroup after adjustment for gender, age, number of exacerbations, and type of airway inflammation. Allele frequencies for CD14 and TLR4 polymorphisms did not show statistical differences between the patients with asthma and the control subjects. Conclusion: CD14 C-159T polymorphisms were not associated with asthma in the adult population in Crimea. TLR4 Asp299Gly polymorphisms were associated with asthma and with decreased odds of nonatopic asthma compared with atopic asthma in the adult population in Crimea.


Author(s):  
Е.П. Нужный ◽  
Н.Ю. Абрамычева ◽  
Е.Г. Воробьева ◽  
Е.О. Иванова ◽  
Ю.А. Шпилюкова ◽  
...  

Синдром CANVAS (мозжечковая атаксия, невропатия и вестибулярная арефлексия) - аутосомно-рецессивная атаксия с поздним дебютом, обусловленная носительством биаллельной экспансии (AAGGG)n во 2-м интроне гена RFC1. До настоящего момента отсутствуют сведения о распространенности данного заболевания в российских семьях. Нами был проведен поиск биаллельной экспансии AAGGG-повторов у 35 российских пациентов с поздней мозжечковой атаксией. Верифицированы 5 пациентов (14,3%) с синдромом CANVAS и характерной клинической картиной. CANVAS (cerebellar ataxia, neuropathy and vestibular areflexia) is a late-onset autosomal recessive ataxia due to biallelic (AAGGG)n repeat expansion in the 2nd intron of the RFC1 gene. There is no information on the CANVAS prevalence in Russian families. We searched for biallelic expansion of AAGGG repeats in 35 Russian patients with late-onset cerebellar ataxia. Five patients (14.3%) with CANVAS syndrome and a characteristic clinical picture were verified.


Author(s):  
И.А. Синельникова ◽  
И.В. Сопрунова ◽  
О.П. Николаева

В статье представлено описание семейного случая миотонической дистрофии Россолимо-Штейнерта-Куршмана-Баттена. Диагноз подтвержден в результате ДНК-диагностики: выявлено увеличенное число копий CTG-повтора гена DMPK, ответственного за развитие миотонической дистрофии. A family case report of Rossolimo-Steinert-Curschmann myotonic dystrophy is presented. An increased number of copies of CTG-repeats of the DMPK gene responsible for the development of MD, i.e., the diagnosis was confirmed by molecular genetic method.


Sign in / Sign up

Export Citation Format

Share Document